From PICO to search terms on the internet: How to find relevant information? New coxibs: Do they have a better gastrointestihal safety?;Du PICO aux termes de recherche par internet: Comment accéder à l'information pertinente? (1) Les nouveaux coxibs: Ont-ils réellement une meilleure sécurité digestive?

Revue Medicale de Liege

Volumn 60, Issue 1, 2005, Pages 52-60

  Van Den Bruel, A ^a,e   Boland, B ^b   Vermeire, E ^c   Buntinx, F ^d   Aertgeerts, B ^d  

^a Ctr Belge d'Evidence Based Medicine   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e Belgian Center for Evidence Based Medicine   (Belgium)

Author keywords

Cox 2; Evidence based medicine; Hip osteoarthritis; Nonsteroidal anti inflammatory drug; Peptic ulcer

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGED; CASE REPORT; COCHRANE LIBRARY; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HIP OSTEOARTHRITIS; HUMAN; INTERNET; KNEE OSTEOARTHRITIS; MEDLINE; OSTEOARTHRITIS; PEPTIC ULCER; REVIEW; RHEUMATOID ARTHRITIS;

AGED; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INFORMATION STORAGE AND RETRIEVAL; INTERNET; LANGUAGE; PRACTICE GUIDELINES; VOCABULARY, CONTROLLED;

EID: 14644445253     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Wallace JL.- Distribution and expression of cyclo-oxygenase iso-enzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med, 1999, 107 (6A), 11S-16S (discussion: 16S-17S).
2. Vane JR, Warner TD.- Nomenclature for cox-2 inhibitors. Lancet, 2000, 356, 1373-1374.
3. Van den Bruel A, Chevalier P, Vermeire E, et al.- Evidence-Based Medicine. Otite moyenne chez l'enfant. Comment formuler une question PICO? Rev Med Liège, 2004, 59, 671-675.
4. Greenhalgh T.- How to read a paper - the MEDLINE database. BMJ, 1997, 315, 180-183.
5. Van den Bruel A, Buntinx F, Aertgeerts B.- Evidence-Based Medicine: plus qu'un terme à la mode. Rev Med Liège, 2004, 59, 669-670.
6. Coenen S, Van den Bruel A.- PICO's beginnen met de juiste vraag: Inleiding op een nieuwe artikelenreeks. Huisarts Nu, 2003, 32, 329-330.
7. Hunt DL, Jaeschke R, McKibbon KA.- Users' guides to the medical literature. XXI Using electronic health information resources in evidence-based practice. JAMA, 2000, 283, 1875-1879.
8. Offringa M, Assendelft WJJ, Scholten RLPM.- Inleiding in evidence-based medicine. Klinisch handelen gebaseerd op bewijsmateriaal. Houten/Diegem: Bohn Stafleu Van Loghum, 2000, 18-30.
9. Haynes RB, Wilczynski N, McKibbon KA, et al.- Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Informatics Assoc, 1994, 1, 447-458.
10. Hunt DL, McKibbon KA.- Locating and appraising systematic reviews. Ann Intern Med, 1997, 126, 532-538.
11. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update.- American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum, 2000, 43, 1905-1915.
12. Technology Appraisal Guidance - N° 27. Londres: National Institute for Clinical Excellence (NHS), 2001.
13. Database of Reviews of Effectiveness. - Upper gastroduodenal ulceration in arthritis patients treated with celecoxib. DARE, 2002, vol. 4.
14. www.jr2.ox.ac.uk/bandolier/band75/b75-2.html.
15. De Vries C.- Cox-II inhibitors versus non steroidal anti-inflammatory drugs in rheumatoid and osteoarthritis patients: gastrointestinal effects. Dans: Foxcroft DR, Muthu V (éd). STEER: Succinct and Timely Evaluated Evidence Reviews 2002; 2(8). Wessex Institute for Health Research and Development, University of Southampton. http://www.signpoststeer.org
16. Deeks JJ, Smith LA, Bradley MD.- Efficacy, tolerability and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ, 2002, 325, 619-626.
17. Van Driel M.- Hoe veilig zijn de nieuwe COX-2-selectieve NSAID's? Huisarts Nu (Minerva), 2001, 30, 263-268.
18. Van Driel M, Art B, Soenen K.- De nieuwe COX-2 selectieven: een aanwinst? Huisarts Nu (Minerva), 2000, 29, 225-229.
19. Chevalier P.- Prévention des ulcères sous AINS: le célécoxib n'est pas plus efficace. MinervaF, 2003, 2, 146-147.
20. Musculoskeletal disorders, Osteoarthritis. What are the effects of oral drug treatment? Londres.- BMJ Clinical Evidence, 2003 (www.clinicalevidence.com) .
21. Henry D, McGettigan P.- Rofecoxib caused fewer endoscopic gastroduodenal ulcers than ibuprofen in osteoarthritis. ACP Journal Club, 2000, 132, 96.
22. Van Driel M, Chevalier P, Janssens I.- AINS cox 2 sélectifs: évaluation après cinq ans. Minerva, 2003, 2, 148-151.